Fasudil
Information
- Drug Name
- Fasudil
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung adenocarcinoma | GATA2 EXPRESSION GATA2 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22541434 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Targeting overactive GATA2-mediated pathways with ... | GATA2 | GATA2 EXPRESSION GATA2 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00120718 | Completed | Phase 2 | The Effect of Fasudil on Vascular Function in Humans | June 2002 | January 2007 |
| NCT00498615 | Completed | Phase 3 | A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon | April 2007 | March 2012 |
| NCT03792490 | Completed | Phase 2 | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | February 20, 2019 | November 1, 2023 |
| NCT06362707 | Not yet recruiting | Phase 2 | Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) | May 1, 2024 | October 1, 2026 |
| NCT01935518 | Unknown status | Phase 2 | A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | September 2013 | May 2015 |
| NCT04734379 | Unknown status | Phase 2 | Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 | January 22, 2021 | November 30, 2023 |